The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer

G. Middleton1,2*, L. R. Crack3, S. Popat4, C. Swanton5,6, S. J. Hollingsworth7, R. Buller8, I. Walker9, T. H. Carr7, D. Wherton3 & L. J. Billingham3

1Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham; 2Department of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham; 3Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham; 4Department of Medicine, Royal Marsden NHS Foundation Trust, London; 5The Francis Crick Institute, London; 6UCL Cancer Institute, CRUK Lung Cancer Centre of Excellence, London; 7Innovative Medicines Oncology, AstraZeneca, Cambridge, UK; 8Pfizer Oncology, Pfizer, San Diego, USA; 9Strategy and Research Funding, Cancer Research UK, London, UK

Received 22 July 2015; revised 28 August 2015; accepted 13 September 2015

Background: The management of NSCLC has been transformed by stratified medicine. The National Lung Matrix Trial (NLMT) is a UK-wide study exploring the activity of rationally selected biomarker/targeted therapy combinations.

Patients and methods: The Cancer Research UK (CRUK) Stratified Medicine Programme 2 is undertaking the large volume national molecular pre-screening which integrates with the NLMT. At study initiation, there are eight drugs being used to target 18 molecular cohorts. The aim is to determine whether there is sufficient signal of activity in any drug–biomarker combination to warrant further investigation. A Bayesian adaptive design that gives a more realistic approach to decision making and flexibility to make conclusions without fixing the sample size was chosen. The screening platform is an adaptable 28-gene Nextera next-generation sequencing platform designed by Illumina, covering the range of molecular abnormalities being targeted. The adaptive design allows new biomarker–drug combination cohorts to be incorporated by substantial amendment. The pre-clinical justification for each biomarker–drug combination has been rigorously assessed creating molecular exclusion rules and a trumping strategy in patients harbouring concomitant actionable genetic abnormalities. Discrete routes of pathway activation or inactivation determined by cancer genome aberrations are treated as separate cohorts. Key translational analyses include the deep genomic analysis of pre- and post-treatment biopsies, the establishment of patient-derived xenograft models and longitudinal ctDNA collection, in order to define predictive biomarkers, mechanisms of resistance and early markers of response and relapse.

Conclusion: The SMP2 platform will provide large scale genetic screening to inform entry into the NLMT, a trial explicitly aimed at discovering novel actionable cohorts in NSCLC.

Clinical Trial ISRCTN: 38344105.

Key words: National Lung Matrix Trial, non-small-cell lung cancer, stratified medicine, adaptive trial design, Umbrella Trial

introduction

The management of patients with non-small-cell lung cancer (NSCLC) has been transformed in the past 10 years. The identification of EGFR-activating mutations as a predictive biomarker for the use of EGFR tyrosine kinase inhibitors ushered in the era of stratified medicine in NSCLC [1]. Only 4 years elapsed between the description of EML4–ALK fusions [2] and the registration of crizotinib for treatment of ALK fusion-positive disease. Alongside, these therapeutic advances have been a change in the regulatory landscape; the provisional registration of crizotinib was based on high signals of activity in non-randomized, single-arm studies [3]. A series of publications culminating in the data from The Cancer Genome Atlas (TCGA) for both adenocarcinoma and squamous cell lung cancer have considerably widened the number of potentially treatable targets, albeit in small molecularly defined patient cohorts [4, 5]. Efficient testing of drug–biomarker combinations is necessary in order to unlock the true potential for stratified medicine for NSCLC. The National Lung Matrix Trial (NLMT), funded by Cancer Research UK in partnership with AstraZeneca/MedImmune and Pfizer, includes many of the potentially actionable molecular aberrations identified in NSCLC. We describe the overarching design of the study and the selection of agents according to molecular abnormality.

methods

The NLMT is a multi-arm non-randomized non-comparative phase II umbrella trial in which patients are allocated to the appropriate targeted therapy according to the molecular genotype of their cancer. The trial includes a
common set of outcome measures for all molecularly defined cohorts with flexibility to select a cohort-specific primary end point. In most cases, response rate is the primary outcome but for agents whose mode of action is likely to be principally cytostatic, progression-free survival (PFS) is preferred. Although randomized trials make it possible to tease out the predictive and prognostic effects of putative biomarkers for therapies, we are looking here for robust signals of activity such as one would expect from a bona fide targeted therapy. For example, the recent demonstration of a 72% response rate and a 19-month median PFS in patients treated with crizotinib harbouring ROS fusions [6] is very clear evidence that this drug works in this cohort of NSCLC patients. Such data, in a very small segment of NSCLC, begin to challenge both the practicality and the need for the traditional randomized trial approach to obtain drug approvals. Indeed, with very small target populations, it will become essential for regulatory science to rapidly evolve if we are to realize the magnitude of the opportunity for precision medicines in cancer.

There is an option within the trial protocol to test any of the given targeted therapies on biomarker-negative patients (i.e. those with no actionable genetic change) if there is evidence of significant activity in the biomarker-positive population. This allows validation of the specificity of the putative biomarker for that drug but may also detect biomarker-negative patients who have impressive responses to the drug and whose tumours can then be analysed to detect abnormalities that may be additional important positive predictive biomarkers of that drug.

The NLMT will be run at all 18 UK Experimental Cancer Medicine Centres (ECMC) with each centre operating a hub and spoke model with patients being referred in from nearby hospitals to the centre. The pace of advances in stratified medicine in lung cancer is such that signal of activity programmes must be nimble, flexible and able to respond promptly to new biomarkers drug combinations being considered. As such, the trial allows for new arms to be entered via substantial amendment, if the international expert review panel and Trial Management Group are convinced of the strength of the pre-clinical data supporting the clinical combination of the biomarker and targeted agent. This will significantly reduce the time from concept to clinical study.

One of the limitations for the development of targeted agents in small patient populations has been the conventional approach to tumour testing which could be described as ‘one drug–one test.’ This limitation will be overcome in the NLMT by implementing an umbrella trial design. This approach will facilitate a transition from a drug-centred approach that has asked ‘can a specific therapeutic agent be given to a patient’, to a patient-centred molecular testing approach which allows the treating physician to ask ‘what is best therapeutic agent for my patient?’

Screening of patients’ tumour biopsies through the Stratified Medicine Programme 2 is performed on a next-generation sequencing (NGS) panel developed and validated by Illumina, carried out in one of three dedicated genotyping centres (Technology Hubs). At present, 28 genes are interrogated but the platform is adaptable to allow new genomic biomarkers to be added. Alignment of tumour DNA reads against germline is mandatory. Careful examination of genetic databases, pre-clinical and clinical data have generated a comprehensive tiering system which ensures that only oncogenically pertinent abnormalities are actioned. Table 1 represents the matrix of molecular cohorts with their targeted agents, together with the predicted frequency of these abnormalities.

the rationale supporting the biomarker/drug combinations in the National Lung Matrix Trial

AZD5353

AZD5363 is potent ATP-competitive AKT inhibitor with IC$_{50}$ <10 nM for all three AKT isoforms. Using a cut-off of GI$_{50}$ <3 μm, 23% of a large cell-line panel were sensitive to inhibition by AZD5363 and three quarters of these had PIK3CA mutations, PTEN loss or HER2 amplification [9]. In vivo activity was demonstrated in both PIK3CA mutant and PTEN inactivated xenograft models. In a study using the PI3K inhibitor GDC-0941, 3/3 PIK3CA amplified cell lines (trial arm F2) were highly sensitive to inhibition and there was no co-occurrence of other obvious oncogenic drivers [10].

Each separate mechanism resulting in AKT activation is treated as a separate cohort. This is an important design feature of the trial. It is unlikely that the activities of targeted agents will be the same for each mechanism of deregulation and treating them all in one cohort may miss the granularity of this response differential. Furthermore, mechanisms of resistance may vary in patients who have an initial response to therapy according to the mechanism of initial AKT activation. Discrete cohort testing allows the specifics of resistance in each molecular cohort to be defined.

All patients’ tumours in this treatment arm will need to be proven to be KRAS wild type. KRAS was shown to be a negative predictive biomarker for AZD5363 response [9]. There is collaborative inactivation of the translational repressor 4E-BP1 by both AKT and ERK signalling [11], ERK directly inactivates TSC2 by phosphorylation [12]. Thus, cells with dual AKT activation and RAS mutation may still inhibit 4E-BP1 even if AKT is inhibited (Figure 1).

AZD4547

AZD4547 is potent inhibitor of FGFR 1, 2 and 3 with IC$_{50}$ values of 0.2, 2.5 and 1.8 nM, respectively [13]. Initial data in NSCLC patients with somatic FGFR amplifications treated with AZD4547 showed modest efficacy (8% PR, 29% SD) but failed to meet the primary end point for continuation [14]. Not all detected FGFR mutations will be eligible. Liao et al. engineered NIH3T3 cells to express the range of separate mutations represented in the squamous cell lung cancer TGCA [15]. Only mutations in the extracellular binding domain, which mediated ligand independent receptor dimerization and activation, and mutations in the intracellular tyrosine kinase domain were transforming and tumorigenic. Those in the trans-membrane spanning region and the terminal portion of the molecule were not transforming, and these two latter will be excluded from testing with the drug.

AZD2014

AZD2014 is an ATP-competitive, selective mTOR kinase inhibitor targeting both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin-insensitive) complexes [16, 17]. AZD2014 is molecularly different from rapalogs and achieves more profound mTORC1 inhibition, in particular, inhibiting phosphorylation of the rapamycin-insensitive site on 4E-binding protein 1 (4E-BP1) (T37/46). AZD2014 also inhibits mTORC2 and has a broader range of growth inhibitory activity in vitro across tumour types compared with rapalogs. mTORC1 inhibition reduces S6K1 activation which negatively represses mTORC2; thus, mTORC1 inhibition releases mTORC2 from S6K1-mediated inhibition and activates AKT via mTORC2-mediated phosphorylation of Ser473 [18] (Figure 1). Inhibition of mTORC2 is therefore important...
because it prevents the activation of AKT via phosphorylation on Ser473 consequent upon inhibition of mTORC1 by rapalogues. Patients with TSC1, TSC2 or LKB1 (STK11) tumour mutations will be eligible for treatment with AZD2014.

The TSC1/2 heterodimer is a GTPase-activating protein which maintains Rheb in its inactive GDP-bound form. Rheb is the upstream activator of mTOR. Hence, when TSC1 or TSC2 activity is lost through mutation, Rheb becomes activated which in turn activates mTOR. TSC mutant cell lines were highly sensitive to inhibition by AZD2014 with all mutants having a GI50 of <1 µM and 8/10 TSC1 mutants having a GI50 <200 nM (AstraZeneca, internal data). A recent clinical study has demonstrated that mTOR inhibitors have significant activity in TSC mutant disease. A patient with anaplastic thyroid cancer who relapsed after surgery and subsequent chemoradiation had an 18-month response to the mTORC1 inhibitor everolimus. Sequencing this patient’s tumour DNA revealed a TSC2 mutation [19].

Loss of LKB1 function phenocopies TSC2 mutation (Figure 1). LKB1 is critical in the activation of AMPK in situations of cellular energy stress, such as hypoglycaemia, which increases the AMP/ATP ratio [20]. AMPK activates TSC2, so when LKB1 is lost, TSC2 is less efficiently activated. mTOR activation causes activation of HIF-1α and this upregulates lysyl oxidase (LOX) activity. This is a key enzyme stabilizing the extracellular matrix via oxidation of lysine residues on collagen and elastin, and such stabilization is important in mediating the process of hypoxia-induced metastasis. Knock-down of LOX in LKB1 mutant cells resulted in reduced anchorage independent cell growth and migration [21]. The LOX inhibitor BAPN had no activity in LKB1 wild-type models but reduced tumour number and volume in LKB1 mutant models.

palbociclib

Palbociclib is a highly selective inhibitor of CDK4/6 kinase activity (IC50 = 11 nM; Ki = 2 nM. Palbociclib has selectivity for CDK4/6, with little or no activity against a large panel of 34 other protein kinases [22].

p16, a product of the CDKN2A locus, is the key inhibitor of the cyclin D1/CDK4 heterodimer (Figure 2). When this dimer is activated, either by homozygous deletion of CDKN2A or amplification of CDK4 or Cyclin D1, Rb becomes phosphorylated. When further phosphorylated by CDK2/Cyclin E, this removes the

| Molecular cohorts and initial estimated prevalence rates | AZD4547 | AZD2014 | Palbociclib | Crizotinib + docetaxel | Selumetinib | AZD5363 | AZD9291 |
|---------------------------------------------------------|---------|---------|-------------|-----------------------|-------------|---------|---------|
| A1: FGFR2/3 mutation—NSCLC [4, 5] | ADC <1.0% ✓ | SCC 4.0% | | | | | |
| B1: TSC1/2 mutation—NSCLC [4] | ADC <1.0% ✓ | SCC 2.7% | | | | | |
| B2: LKB1 mutation—NSCLC [4, 5] | ADC 8.8% ✓ | SCC 1.6% | | | | | |
| C1: Proficient Rb and p16 loss—SCC [4] | SCC 29.0% ✓ | | | | | | |
| C2: Proficient Rb and p16 loss—ADC [4] | ADC 19.6% ✓ | | | | | | |
| C3: Proficient Rb and CDK4 amplification—NSCLC [4, 5] | ADC7.0% ✓ | SCC <1.0% | | | | | |
| C4: Proficient Rb and CCND1 amplification—NSCLC [4, 5] | ADC5.0% ✓ | SCC 12.0% | | | | | |
| C5: Proficient Rb and KRAS mutation—ADC [5] | ADC25.8% ✓ | | | | | | |
| D1: Met amplified—NSCLC | ADC 2.7% ✓ | SCC 1.4% | | | | | |
| D2: ROS1 rearranged—NSCLC [6] | ADC 1.7% ✓ | SCC <1.0% | | | | | |
| E1: NF1 mutation—SCC [4] | SCC 5.8% ✓ | | | | | | |
| E2: NF1 mutation—ADC [4] | ADC 4.6% ✓ | | | | | | |
| E3: NRAS mutation—ADC [7] | ADC 0.7% ✓ | | | | | | |
| F1: PIK3CA mutation—SCC [8] | SCC 11.0% ✓ | | | | | | |
| F2: PIK3CA amplification—SCC [4] | SCC 15.0% ✓ | | | | | | |
| F3: PI3K/AKT deregulation | | | | | | | |
| P3KCA mutation and amplification—ADC [8] | ADC 2.0% ✓ | | | | | | |
| PTEN mutation and loss (ADC) [5] | ADC 3.0% ✓ | | | | | | |
| AKT1 mutation (NSCLC) [4, 5] | ADC 0.5% ✓ | SCC 0.5% | | | | | |
| F4: PTEN loss and mutation—SCC [4] | SCC 20.0% ✓ | | | | | | |
| G1: EGFR mutation and T790M + NSCLC | ADC 8% ✓ | SCC <1% | | | | | |
inhibitory activity of RB upon E2F1, resulting in the liberation of E2F and the passage of cancer cells through the G1/S checkpoint. In patients whose cancers harbour one of these three molecular abnormalities and would be eligible for treatment with palbociclib, it must be demonstrated that their cancer harbours no concomitant loss of Rb function. In a panel of ovarian cancer cell lines, Rb-proficient cells with low p16 expression (by message or protein expression) were the most sensitive to palbociclib, and no other analysed biomarkers pertaining to CDK4/6 signalling were informative [23]. Expression profiles of cells classified by response to palbociclib demonstrated 117 differentially expressed genes between sensitive and resistant lines: CDKN2A was the most significant gene. KRAS mutant adenocarcinoma represents a significant molecular cohort of lung adenocarcinoma. It was demonstrated that loss
of CDK4 activity was synthetically lethal with KRAS mutation in lung adenocarcinoma [24]. This effect was specific: it was not seen in vivo with knock-down of the other CDKs and was not seen in other mutant KRAS expressing tissues including the pancreas. Palbociclib was shown to have significant activity in KRAS mutant genetically engineered mouse models. The mechanism of synthetic lethality appeared to be due to the re-induction of senescence. KRAS mutation causes oncogene-induced senescence and for the development of the full malignant phenotype, KRAS mutant cells must bypass senescence. Thus, CDK4 inhibition is expected to abrogate this bypass in patients whose lung cancers harbour an intact Rb signalling pathway and a KRAS mutation. Activated RAS induces the formation of senescence-associated heterochromatin foci by activating GSK3β which phosphorylates the histone chaperone HIRA facilitating its localization to PML nuclear bodies [25]. AKT activation inhibits RAS-mediated oncogene-induced senescence in part through the inhibitory phosphorylation of GSK3β at serine 9 [26]. Thus, a molecular exclusion for this arm is concomitant abnormalities which result in AKT activation, such as PIK3CA mutation, PTEN loss or AKT mutation.

**crizotinib**

Crizotinib is a potent inhibitor of both MET and ROS1. There is already clear evidence of activity of crizotinib in patients with tumour MET amplification [27] or ROS1-rearranged lung cancer [6]. These arms as well as adding to the global database of preliminary activity of this drug in these cohorts will also provide access for patients with these actionable molecular aberrations.

**AZD9291**

About 50%–60% of patients with EGFR mutation-positive tumours progressing after first-line treatment on an EGFR TKI become resistant via the acquisition of the secondary gatekeeper mutation T790M. AZD9291 is an oral, potent, selective, irreversible inhibitor of both EGFR-TKI-sensitizing and T790M resistance mutations. In 127 assessable patients with T790M disease, a response rate of 61% and median PFS of 9.6 months was observed [28]. Patients who have received a first-line EGFR TKI will be invited to have a repeat biopsy on progression and, if their cancers have acquired the T790M mutation, treatment with AZD9291 will be offered.

**selumetinib and docetaxel**

Selumetinib is a potent, selective, allosteric MEK inhibitor. In a randomized phase II study, it was demonstrated that a combination of selumetinib plus docetaxel significantly improved response rate and PFS when compared with docetaxel alone as second-line therapy for patients with KRAS mutant adenocarcinoma of the lung [29]. This combination is currently in phase III in this setting. In the lung adenocarcinoma TCGA, NF1 mutations were found to be significantly represented in cancers not harbouring abnormalities of RAS, RAF or receptor tyrosine kinases [11]. The authors specifically identified NF1 as an important driver event in oncogene-negative adenocarcinoma. NF1 is a RAS GAP (Figure 1). It restricts RAS activation by catalysing the intrinsic GTPase activity of RAS. Thus, when NF1 is inactivated by mutation, RAS becomes locked in its GTP-bound form resulting in constitutive activation. Hence, NF1 loss phenocopies KRAS mutation and patients with such cancers can also be considered a suitable molecular cohort to treat with the selumetinib/docetaxel combination, which has proven benefits in KRAS mutant disease. There is good clinical evidence for the importance of MEK signalling in NF1 mutation. Patients with germline inactivation of NF1 develop pleomorphic neurofibromas (PNs); in a cohort of PN patients aged 3–18, all patients treated with single-agent selumetinib demonstrated volumetric reduction in the size of their PNs [7].

In patients whose tumours harbour NRAS mutations, there appear to be no other obvious driver mutations [30]. 5/6 NRAS mutant lung cancer cell lines were sensitive to single-agent selumetinib and MEK signalling appeared to be significantly more important than PI3K/AKT activation given the lack of effect of GDC-0941 in these NRAS mutant lung cancer cell lines. Thus, we will treat patients with NRAS mutant tumours as a separate cohort with this combination.

**no actionable mutation arm**

A secondary objective of the trial is to offer a therapeutic option for patients with successful screening in the trial but without specific eligibility for one of the targeted genomic aberrations at that moment in time. The first in a planned series of drugs that we are testing in this cohort is MEDI4736, an anti-PDL1 monoclonal antibody with clear evidence of activity in patients with NSCLC [31].

**concluding remarks**

The NLMT is an ambitious adaptive programme which seeks to increase the number of actionable genetic abnormalities in NSCLC. Key translational components include voluntary pre-treatment biopsies to identify potential predictive biomarkers post-treatment biopsies to ascertain mechanisms of resistance, and the development of PDX models wherever possible. ctDNA is being collected pre-, during and post-treatment. Repeat biopsies can be difficult to obtain: the recent identification of the C797S mutation in the plasma of patients with T790M mutation-positive disease treated with AZD9291 in second line or beyond demonstrates the utility of liquid biopsies to identify mechanisms of resistance to targeted therapies [32].

Ensuring the sustainability of NLMT is important in order to maximize the information that can be obtained from this programme. We are in discussion with a number of other potential pharma partners and have already discussed with our current pharma collaborators plans for treatment of patients with p53 loss and patients with rarer but potentially actionable mutations such as those with ATM loss and exon 14 slipping mutations in MET. Finally, the NLMT is clearly not the only such programme in this therapy space. The NCI-MATCH co-operative group trial currently has 10 arms: some cohorts are in common with NLMT but NCI-MATCH also covers BRAF mutations (dabrafenib/trametinib), HER2 mutations (afatinib), HER-2 amplification, NTRK fusions (selpercatinib), and c-kit mutations (sunitinib). Integrating the data from this trial together with data from NLMT, other key trials such as SAFIR-02 (NCT02117167) and LUNGMAP (NCT02154490), and further data arising from national genomic screening initiatives such as The Lung Cancer Genome Project (Network Genomic Medicine, Cologne) and LC-SCRM (Japan),...
will allow the development of a global database of outcomes on personalized medicines in NSCLC.

acknowledgements

This work has been supported by the Birmingham Experimental Cancer Medicine Centre, and the Early Drug Development team in the Cancer Research UK Clinical Trials Unit, University of Birmingham; particularly Kristian Brock and Susannah Brown, and Robert Ewen (AstraZeneca) for his contribution to the actionable mutations list. Members of the National Lung Matrix Trial Management Group, Trial Steering Committee and Trial Arm Lead Investigators: Clive Mulatero, James Spicer, Yvonne Summers and Timothy A. Yap. SP acknowledges NHS funding to the RMH/ICR NIHR Biomedical Research Centre.

funding

This work is supported by Cancer Research UK (C22436/A18392 and C11497/A19363), AstraZeneca/MedImmune and Pfizer (provision of Investigational Medicinal Products). Note that the Pharma Partners are providing core funding into the Stratified Medicine Programme in addition to the compounds.

disclosure

GM receives research funding from AstraZeneca and Cancer Research UK. SP is non-compensated consultant to AstraZeneca and Pfizer. LB has received personal fees from Eli Lilly and Roche outside of the submitted work. All remaining authors have declared no conflicts of interest.

references

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21): 2129–2139.
2. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448(7153): 561–566.
3. Kwak EL, Bang YJ, Camidge DR. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363(18): 1693–1703.
4. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of non-small-cell lung cancers. Nature 2012; 489(7417): 519–525.
5. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511(7511): 543–550.
6. Shao AT, Ou Sh, Bang YJ et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370(21): 1963–1971.
7. Widemann BC, Marcus LJ, Fisher MJ et al. Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). J Clin Oncol 2014; 32(5s suppl): abstr 10018.
8. Scheffler M, Bos M, Gardizi M et al. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget 2015; 6(21): 1315–1326.
9. Davies BR, Greenwood H, Dudley P et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT; pharmacodynamics, antitumour activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012; 11(4): 873–887.
10. Soperke JM, O’Brien C, Huw L et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 2012; 18(24): 6771–6783.
11. She QB, Halliwcl E, Ye Q et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrate functions in tumors. Cancer Cell 2010; 18(1): 39–51.
12. Ma L, Chen Z, Enqument-Biromge H et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121(2): 179–193.
13. Gavinre PR, Mooney L, Kilgour E et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 72(8): 2045–2056.
14. Paik PK, Shen R, Ferry D et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: preliminary antitumor activity and pharmacodynamic data. J Clin Oncol 2014; 32(5s suppl): abstr 8035.
15. Liao RG, Jung T, Tchaicha J et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 2013; 73(16): 5195–5205.
16. Guichard SM, Howard Z, Heathcote D et al. AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer. In Proceedings AACR 103rd Annual Meeting (Abstr 917), McCormick Place West 2012; 72.
17. Pipe KG, Malagk U, Hummersone MG et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 2013; 23(5): 1212–1216.
18. Dibbole CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 2009; 29(21): 5657–5670.
19. Wagle N, Grabiner BC, Van Allen EM et al. Brief report: response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 2014; 371: 1426–1433.
20. Shaw RJ, Bardessey N, Manning BD et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004; 6(1): 91–99.
21. Gao Y, Xiao Q, Ma H et al. LB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci USA 2010; 107(44): 18892–7.
22. Fry DW, Harvey PJ, Keller PR et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumour activity in human tumour xenografts. Mol Cancer Ther 2004; 3(11): 1427–1438.
23. Konecny GE, Winterhoff B, Kolarova T et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Cancer Res Clin Cancer Res 2011; 17(6): 1591–1602.
24. Poyel M, Martin A, Dubus P et al. A synthetic lethal interaction between K-Ras oncoproteins and CDK4 unveils a therapeutic strategy for non-small cell lung cancer. Cancer Cell 2010; 18(1): 63–73.
25. Ye X, Zerlanto B, Kennedy A et al. Downregulation of Wnt signaling is an early signal for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell 2007; 27(2): 183–196.
26. Kennedy AL, Mornon JP, Manoharan I et al. Activation of the PIKC3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 2011; 42(1): 36–49.
27. Camidge DR, Ou S-H, Shapiro GI et al. Efficiency and efficacy of crizotinib in patients with advanced MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 2014; 32(5s suppl): abstr 8001.
28. Jänne PA, Yang JC, Kim DW et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372(18): 1689–1699.
29. Jänne PA, Shaw AT, Pereira JR et al. Activating PI3KCA mutations in non-small-cell lung cancer: a randomised, multicentre, placebo-controlled phase 2 study. Lancet Oncol 2013; 14(1): 38–47.
30. Oshahi K, Sequist LV, Arcila ME et al. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res 2011; 17(9): 2584–2591.
31. Segal NH, Ou SH, Balmanoukian AS et al. Safety and efficacy of MED4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J Clin Oncol 2015; 33(suppl): abstr 3011.
32. Thress KS, Paezetz CP, Felip E et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015; 21(6): 560–562.